Navigation Links
LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
Date:11/9/2011

THE WOODLANDS, Texas, Nov. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center will be presenting data from Lexicon's LX2931 Phase 2 proof-of-concept clinical trial at the annual meeting of the American College of Rheumatology on Wednesday, November 9, 2011 in Chicago, Illinois.  LX2931 is an orally-administered small molecule designed to inhibit sphingosine-1-phosphate lyase (S1P), an enzyme in a pathway known to be important in regulating the immune response.  

Results from the Phase 2a study demonstrated a favorable safety profile at all doses tested and suggested that patients with rheumatoid arthritis treated with 150 mg of LX2931 once daily showed improvement in the primary efficacy endpoint of the study, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12.

For more information on this program or to download a copy of the presentation, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
2. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
3. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
4. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
5. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
6. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
7. Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 The global market for human ... introduction of new vaccines. These new products and ... Market. The Kalorama information report examines the global ... developmental vaccines for diseases that are already vaccine-preventable. ... entire communities from diseases spread by person-to-person transmission. ...
(Date:10/27/2014)... , Oct. 27, 2014  RenovoRx, a leading developer ... and delivery of fluids to selected sites in the ... Directors has appointed Shaun Bagai as Chief ... RenovoRx Board of Directors. Bagai brings more than 15 ... Bagai joined RenovoRx in June 2014 and in ...
(Date:10/27/2014)... , Oct. 27, 2014  In the last few weeks, Ebola ... Africa to a worldwide crisis when a traveler ... virus and died, and two nurses were infected. While ... happen, the use of modern technology, such as electronic health records ... This week, InformationWeek Healthcare Editor Alison Diana ...
Breaking Medicine Technology:Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3RenovoRx Board Names Shaun R. Bagai as CEO 2EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3
... SAN DIEGO, Jan. 17, 2012  Janssen Research & ... San Diego, a 30,000-square-foot life science innovation center, ... Center.  The innovation center provides a capital efficient, ... technologies and research platforms to advance medical care. ...
... Jan. 17, 2012   ULURU Inc. (NYSE AMEX: ... Melmed Holdings AG for the marketing of Altrazeal® ... Africa has been finalized. Under the terms of ... marketing of Altrazeal® to Melmed Holdings AG, who are establishing ...
Cached Medicine Technology:Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego 2Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego 3Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego 4ULURU Inc. Completes Altrazeal® License Agreement for Europe 2ULURU Inc. Completes Altrazeal® License Agreement for Europe 3
(Date:10/30/2014)... by NIH grantees predicts that women must take the ... vaginal sex, whereas just two doses per week can ... finding helps explain why two large clinical trials testing ... show efficacy. Participants in the VOICE and ... antiretroviral) for HIV prevention were counseled to take one ...
(Date:10/30/2014)... Pompano Beach, Florida (PRWEB) October 30, 2014 ... surprise Halloween visit to Pompano Beach firefighters, showing that ... your community. , Timothy met firefighters Tracey and ... sponsored by Galuppi’s Restaurant and the Pompano Beach Chamber ... and outside the fire truck, letting Timothy wear his ...
(Date:10/30/2014)... NC (PRWEB) October 30, 2014 Don ... commercial, and health insurance plans for North Carolina residents, ... satellite office in Burlington’s Holly Hill Mall. The new ... with agents already helping customers through all facets of ... purchase. , Allred Insurance spokesman Scott Allred couldn’t be ...
(Date:10/30/2014)... 2014 Five months after their expansion, ... LLC announces new branding and a website to accompany ... After David Mepham’s promotion to name partner earlier this ... to include Mepham’s name and better reflect their combined ... firm, the decision to implement new branding reflects Hodgkinson ...
(Date:10/30/2014)... 30, 2014 Paramount Rx, a full-service ... increasing efforts to help people save money through its ... increase for prescription drugs in the new health care ... resources to bridge the relationship between consumers, businesses and ... biggest challenges people face today with medical costs is ...
Breaking Medicine News(10 mins):Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3
... Discussion focuses on innovative programs, partnerships, and ... intergenerational mentoring in the workplace, WOONSOCKET, ... developing innovative workforce programs to recruit and retain,employees, was ... Aging,in America Conference in Washington, D.C. for a discussion ...
... Cardiology ... - FDA appeal progressing, TORONTO, March 28 /PRNewswire-FirstCall/ ... audited financial results,for the year ended December 31, 2007., "During ... and CEO. We made tremendous progress on,several fronts, including a License, ...
... The Pennsylvania,Health Care Cost Containment Council (PHC4) announced ... stepping down as head of the,innovative health care agency. ... his last day of employment has not yet been ... became Executive Director in,1998., "Marc has been a ...
... is Professor Patrick Tam from the Childrens Medical Research Institute, ... the Australian Academy of Science. , Peter Doherty, Ian Frazer ... have been honoured by election to the academy. Professor Tam ... , Professor Tam and his team have recently completed a ...
... NEW YORK, March 28 /Xinhua-PRNewswire-FirstCall/ -- China ... "Company") a leading,provider in the nutraceutical industry ... organic nutritional food products,supplements, and personal care ... in the final stages of the acquisition ...
... WELLINGTON, Fla., March 28 The Quantum ... announced today that,the Board of Directors and Noel ... have reached an agreement to amend his existing,employment ... of employment,with the Company. The terms of the ...
Cached Medicine News:Health News:CVS Caremark Presents at NCOA-ASA Conference on Company's Commitment to Recruiting and Retaining Mature Workers 2Health News:CVS Caremark Presents at NCOA-ASA Conference on Company's Commitment to Recruiting and Retaining Mature Workers 3Health News:PreMD Reports Fiscal 2007 Results 2Health News:PreMD Reports Fiscal 2007 Results 3Health News:PreMD Reports Fiscal 2007 Results 4Health News:PreMD Reports Fiscal 2007 Results 5Health News:PreMD Reports Fiscal 2007 Results 6Health News:PreMD Reports Fiscal 2007 Results 7Health News:PreMD Reports Fiscal 2007 Results 8Health News:PreMD Reports Fiscal 2007 Results 9Health News:PreMD Reports Fiscal 2007 Results 10Health News:PreMD Reports Fiscal 2007 Results 11Health News:PreMD Reports Fiscal 2007 Results 12Health News:National recognition for top scientist 2Health News:China Yingxia International Announces Soybean Milk Production Lines Acquisition 2Health News:The Quantum Group Extends CEO's Employment Agreement 2Health News:The Quantum Group Extends CEO's Employment Agreement 3
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve....
Goldman single hook....
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl...
Medicine Products: